Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Kai Michael Beeh1 Insaf Respiratory Research Institute Wiesbaden, Wiesbaden, Germany, [email protected]Correspondence[email protected]

Anne-Marie Kirsten2 Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

Ana-Maria Tanase3 Novartis Pharma AG, Basel, Switzerland

Alexia Richard3 Novartis Pharma AG, Basel, Switzerland

Weihua Cao4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Bettina Hederer3 Novartis Pharma AG, Basel, Switzerland

Jutta Beier1 Insaf Respiratory Research Institute Wiesbaden, Wiesbaden, Germany, [email protected]

Oliver Kornmann5 IKF Pneumologie, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany

Richard N van Zyl-Smit6 Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa

show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Piotr Damiański, Grzegorz Kardas, Michał Panek, Piotr Kuna & Maciej Kupczyk. (2022) Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions. Expert Opinion on Drug Safety 21:4, pages 499-515.
Read now

Articles from other publishers (6)

A.L. Aguilar-Shea & C. Gallardo-Mayo. (2022) Revisión narrativa de la terapia inhalatoria en la EPOC. Medicina de Familia. SEMERGEN 48:3, pages 214-218.
Crossref

Thomas E. Tarara, Danforth P. Miller, Audrey E. Weers, Ariel Muliadi, Jerry Tso, Avi Eliahu & Jeffry G. Weers. (2022) Formulation of Dry Powders for Inhalation Comprising High Doses of a Poorly Soluble Hydrophobic Drug. Frontiers in Drug Delivery 2.
Crossref

Yoen-Ju Son, Danforth P. Miller & Jeffry G. Weers. (2021) Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler. Pharmaceutics 13:9, pages 1528.
Crossref

Tamara Alonso-Pérez, Elena García-Castillo & José Luis López-Campos. (2021) Escalando y desescalando el tratamiento en la enfermedad pulmonar obstructiva crónica. ¿El inhalador importa?. Archivos de Bronconeumología 57:9, pages 604-605.
Crossref

Tamara Alonso-Pérez, Elena García-Castillo & José Luis López-Campos. (2021) Escalation and de-escalation of therapy in chronic obstructive pulmonary disease. Is the inhaler important?. Archivos de Bronconeumología (English Edition) 57:9, pages 604-605.
Crossref

Sawittree Sahakijpijarn, Hugh D.C. Smyth, Danforth P. Miller & Jeffry G. Weers. (2020) Post-inhalation cough with therapeutic aerosols: Formulation considerations. Advanced Drug Delivery Reviews 165-166, pages 127-141.
Crossref

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Citations (7)

Read on this site (1)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date